



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

10-16-01
PATENT
Attorney Docket No. 015542-002330US
Client Ref. No. 121

Assistant Commissioner for Patents
Washington, D.C. 20231

On October 5, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Green *et al.*

Application No.: 09/506,430

Filed: February 17, 2000

For: PHARMACEUTICAL
ANGIOSTATIC DIPEPTIDE
COMPOSITIONS AND METHODS OF
USE THEREOF

Examiner: Luxton, David

Art Unit: 1653

RESPONSE TO RESTRICTION
REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the restriction requirement mailed September 8, 2001, Applicants elect, with traverse, Group 8, drawn to a method of inhibiting neovascularization by administering a compound recited in claim 18, with the proviso that G8 is excluded. Claims readable thereon include claims 18, 19, 21, 22, 28-35, and 39. Applicants elect, with traverse, pyroGlu-Trp (pGlu-Trp-OH) as the peptide species. Applicants elect, with traverse, malignant tumors as the specific disorder that is the target of the treatment. Reconsideration is respectfully requested.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Eric J. Baude
Reg. No. 47,413

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
EJB
SF 1276211 v1